MergerApr 30, 2026, 08:38 AM
CYCN Amends 10-K; Reaffirms Korsana Biosciences Merger Expected Q3 2026
AI Summary
Cyclerion Therapeutics, Inc. filed an amendment to its Form 10-K to include information required by Part III (Items 10-14), as it does not intend to file an annual meeting definitive proxy statement. The amendment also reiterates the previously announced proposed merger with Korsana Biosciences, Inc., which is expected to close in Q3 2026, pending shareholder approvals. The filing details the company's board of directors, executive compensation, corporate governance, and committee structures.
Key Highlights
- CYCN entered a merger agreement with Korsana Biosciences, Inc. on April 1, 2026.
- Merger is anticipated to close in the third quarter of 2026, subject to shareholder approvals.
- Amendment to Original Form 10-K includes Part III information (Items 10-14).
- Board of Directors consists of six members, including Chairman Errol B. De Souza, Ph.D.
- Four directors (Drs. Hyman, Katabi, De Souza, and Mr. Higgins) are independent per Nasdaq standards.
- Audit Committee is chaired by Michael F. Higgins, who is an "audit committee financial expert."
- Compensation Committee is chaired by Errol B. De Souza, Ph.D.
- Nominating and Corporate Governance Committee is chaired by Steven E. Hyman, M.D.